National Health Investors, Inc. (NHI) Stock Price & Analysis
National Health Investors, Inc. (NHI) closed at USD 66.96 on Thursday, October 22, 2026, up 3.14% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 64.92; the Oct 22, 2026 session ranged USD 65–67.15 on volume of 235,427 shares. Market capitalization is $3.29B, with a 52-week range of USD 63.51–91.38 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NHI.md
Key facts (NHI)
- Last four reported quarters (through Jun 30, 2026): revenue $432M, net income $167M (38.6% margin) (SEC filings).
- Valuation: P/E 19.7x (avg 21.8x at the last 3 fiscal year-ends), net debt $1.24B.
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $167K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.38 on a 1–5 scale) (8 analysts), mean target USD 78.5 (range 65–90).
- Total return with dividends: 1Y -6.6% vs S&P 500 +14.9%; 5Y +58.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-09, EPS estimate USD 1.51, revenue estimate $112M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NHI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $299M | $278M | $320M | $335M | $376M | $432M |
| Net income | $112M | $66.4M | $136M | $138M | $142M | $167M |
| EPS (diluted) | $2.44 | $1.48 | $3.13 | $3.13 | $3.02 | — |
| Free cash flow | $161M | $174M | $135M | $49.8M | -$57.5M | — |
| Net margin | 37.4% | 23.9% | 42.4% | 41.2% | 37.9% | 38.6% |
| Revenue growth | -10.2% | -6.9% | +15.0% | +4.8% | +12.1% | — |
| Cash + short-term investments | $37.4M | $19.3M | $22.3M | $24.3M | $19.6M | — |
| Total debt | $1.24B | $1.15B | $1.14B | $1.15B | $1.16B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NHI)
P/E 19.7x · P/S 7.6x · EV/Sales 10.5x · P/B 2.1x · Earnings yield 5.07% · Dividend yield (paid, TTM) 5.34% · Net debt $1.24B · EV $4.53B
P/E at fiscal year-ends: Dec 2025 25.3x, Dec 2024 22.1x, Dec 2023 17.9x.
Insider purchases (SEC Form 4, open-market, last ~7 months) (NHI)
2 purchases, $167K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-15 | McCabe Robert A Jr | Director | 890 | $64K | 71.65 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-06-05 | Mendelsohn D. Eric | CEO and President | 1,500 | $103K | 68.84 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NHI)
Consensus Buy (mean 2.38 on a 1–5 scale), 8 analysts; mean target USD 78.5 (low 65, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Wells Fargo | Target lowered | Equal-Weight | $78 → $68 |
| 2026-09-02 | Truist Securities | Target lowered | Buy | $81 → $80 |
| 2026-09-01 | Wells Fargo | Target lowered | Equal-Weight | $79 → $78 |
| 2026-06-25 | Deutsche Bank | Target lowered | Hold | $85 → $80 |
Total return (dividends reinvested) (NHI)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -6.6% | +58.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -6.6% | +9.6% |
| Volatility (annualized) | 23.8% | 22.4% |
| Max drawdown | -27.1% (Feb 2026→Oct 2026) | -24.6% (Feb 2026→Oct 2026) |
Companies that name NHI in their SEC reports
| Relationship to NHI | Company | Filing | Sentence |
|---|---|---|---|
| partner | NATIONAL HEALTHCARE CORP (NHC) | 10-K Feb 26, 2026 | “There is no assurance, however, that we will reach agreement with NHI on the base rent or other renewal terms.” |
NHI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.51 | $1.96 | -23.0% | $112.2M | 3 |
| Next quarter (ends Dec 2026) | $0.79 | $2.67 | -70.4% | $114.7M | 1 |
| Current fiscal year (ends Dec 2026) | $4.05 | $3.77 | +7.7% | $457.3M | 4 |
| Next fiscal year (ends Dec 2027) | $3.45 | $3.31 | +4.2% | $487.7M | 1 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 66.96 |
|---|---|
| Change | ▲ 3.14% (up) |
| Previous Close | USD 64.92 |
| Open | USD 65.06 |
| Day Range | USD 65 – 67.15 |
| 52-Week Range | USD 63.51 – 91.38 |
| Volume | 235,427 shares |
| Market Cap | $3.29B |
| Exchange | NYQ |
Technical Analysis (NHI)
Nexqual's technical model rates NHI "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.73 (neutral) |
| vs SMA50 | Below (USD 68.86) |
| MACD | -0.82 (negative) |
Analyst Ratings (NHI)
Wall Street analysts rate NHI "Buy" based on 8 analysts, with a mean price target of USD 78.5 (range USD 65–90), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 78.5 |
| High Target | USD 90 |
| Low Target | USD 65 |
| Buy / Hold / Sell | 5 / 3 / 0 |
Earnings (NHI)
| Next Earnings Date | 2026-11-09 |
|---|---|
| Revenue Estimate | $112.16M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.15 vs est 4.57 ▼ miss |
| 2026-03-31 | USD 0.77 vs est 0.86 ▼ miss |
| 2025-12-31 | USD 0.76 vs est 0.8 ▼ miss |
| 2025-09-30 | USD 0.69 vs est 0.6 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (NHI)
| Total Revenue | $435.78M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +33.80% |
| Gross Margin | +73.92% |
| Operating Margin | +41.09% |
| Profit Margin | +38.27% |
| ROE | +10.72% |
| Debt / Equity | 0.8 |
| Current Ratio | 1.82 |
| Total Cash | $30.39M |
| Total Debt | $1.28B |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$57.47M (-15.3% of revenue) |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (NHI)
Nexqual rates National Health Investors, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 41% (last 12 months) |
| Balance Sheet | Mixed — $30M cash and investments vs $1.27B debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$57M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Mixed — ROE 11%, ROA 4.4% |
Ownership (NHI)
| Insider Ownership | +2.39% |
|---|---|
| Institutional Ownership | +79.21% |
| Shares Outstanding | 49.11M |
| Float | 47.94M |
| Short % of Float | +4.99% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (NHI)
National Health Investors, Inc. is led by D. Eric Mendelsohn, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| President, CEO & Director | D. Eric Mendelsohn |
|---|---|
| Chief Financial Officer | Todd M. Siefert |
| EVP & Chief Operating Officer | Christian K.S. Maingot |
| Senior Vice President of Finance & Investor Relations | Dana Rolfson Hambly |
| Director of Corporate Compliance & Human Resources | Kimberly Ouimet |
Major Backers & Investors (NHI)
Notable institutional backers of National Health Investors, Inc. include Principal Financial Group, Inc., Bank of America Corporation, Charles Schwab Investment Management, Inc., according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Principal Financial Group, Inc. | 4.03% |
| Bank of America Corporation | 2.08% |
| Charles Schwab Investment Management, Inc. | 1.79% |
| Nomura Asset Management International Inc | 1.77% |
| Principal Funds, Inc-Real Estate Securities Fund | 1.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 17.78% |
| Vanguard Group | 13.7% |
| State Street | 5.57% |
| BNY Mellon | 3.27% |
| Geode Capital | 2.86% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LTC | LTC Properties, Inc. | USD 43.33 | ▲ 2.7% |
| SBRA | Sabra Health Care REIT, Inc. | USD 19.6 | ▲ 3.7% |
| DHC | Diversified Healthcare Trust | USD 7.87 | ▲ 2.34% |
| HR | Healthcare Realty Trust Incorpo | USD 17.93 | ▲ 4% |
| MPT | Medical Properties Trust, Inc. | USD 2.71 | ▲ 3.04% |
| CTRE | CareTrust REIT, Inc. | USD 36.62 | ▲ 2.72% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt